Usefulness of fluorine‐18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck

Abstract

Background. Residual structural abnormalities after definitive treatment of head and neck squamous cell carcinoma (HNSCC) are common and pose difficult management problems. The usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) to supplement conventional evaluation with clinical and standard radiologic examination (CE) in such patients was assessed.Methods. Fifty-three eligible patients were identified with residual structural abnormalities on CE. True disease extent could be validated in 46 patients. Patients had a median potential follow-up of 55 months (range, 41 -75 months) from the date of PET scan to the analysis closeout date.Results. PET had better diagnostic accuracy than CE (p = .0002) and induced management change in 21 patients (40%; 95% confidence interval [CI], 26% -54%), including avoidance of unnecessary planned surgery in 14 patients with negative PET. Appropriate management change was confirmed in 19 (95%) of 20 evaluable cases. Disease presence and extent assessment by PET were significant predictors of survival (p < .0001), whereas the extent of disease determined by CE was not.Conclusion. PET added significantly to the value of CE in restaging disease in patients with structural abnormalities after definitive treatment of HNSCC. Management decisions based on PET were appropriate in most patients. A

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

“…49,78). In addition, FDG-PET can define the extent of the primary disease before and after chemoradiotherapy; in contrast to estimates based on conventional imaging, the FDG-PETdefined extent of disease was a significant predictor of survival (P < 0.0001) in one recent study (79). FDG-PET is particularly accurate for staging local nodal spread, a key factor for prognosis and treatment planning.…”

“…In detection of recurrent disease, FDG-PET has greater sensitivity and specificity than conventional imaging; CT is limited by the anatomic distortion commonly seen following treatment due to inflammation and edema and typically requires serial examinations. In 53 patients with residual structural abnormalities following definitive treatment, FDG-PET changed patient management in 40%; planned surgery was determined to be futile in 14 patients based on negative FDG-PET scan (79). Indeed, FDG-PET has a high negative predictive value (89% in one study of 75 patients; ref.…”

15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma

“…As the clinical role of PET has continued to evolve, there has been increasing evidence reporting a strong correlation with metabolic response and prognosis after chemoradiation in malignancy. Our institution has previously reported the powerful prognostic stratification achieved by 18 F-FDG PET metabolic response across a range of cancer types (7)(8)(9)(10)(11)(12).…”

Usefulness of 3′-Deoxy-3′-18F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

“…Several studies have suggested that 18 F-FDG PET might be useful for assessment of therapeutic responses (3)(4)(5)(6). However, 18 F-FDG is also metabolized at sites of inflammation and in other reactive states, so that false-positive results may be obtained because of inflammatory changes remaining within the first few posttreatment months.…”